Bioventus Inc. (BVS)
Bioventus Statistics
Share Statistics
Bioventus has 66.16M shares outstanding. The number of shares has increased by 3.65% in one year.
| Shares Outstanding | 66.16M |
| Shares Change (YoY) | 3.65% |
| Shares Change (QoQ) | 1.21% |
| Owned by Institutions (%) | 69.71% |
| Shares Floating | 45.19M |
| Failed to Deliver (FTD) Shares | 708 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 922.37K, so 1.41% of the outstanding shares have been sold short.
| Short Interest | 922.37K |
| Short % of Shares Out | 1.41% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is -13.97 and the forward PE ratio is 18.5. Bioventus's PEG ratio is 0.2.
| PE Ratio | -13.97 |
| Forward PE | 18.5 |
| PS Ratio | 1.2 |
| Forward PS | 1 |
| PB Ratio | 4.64 |
| P/FCF Ratio | 17.69 |
| PEG Ratio | 0.2 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bioventus.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.31 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.55 |
| Debt / FCF | 0.7 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $616.43K |
| Profits Per Employee | $-52.82K |
| Employee Count | 930 |
| Asset Turnover | 0.79 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -49.13M |
| Effective Tax Rate | 100% |
Stock Price Statistics
The stock price has increased by 85.6% in the last 52 weeks. The beta is 0.92, so Bioventus's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | 85.6% |
| 50-Day Moving Average | 10 |
| 200-Day Moving Average | 9.94 |
| Relative Strength Index (RSI) | 42.95 |
| Average Volume (20 Days) | 320.22K |
Income Statement
In the last 12 months, Bioventus had revenue of 573.28M and earned -49.13M in profits. Earnings per share was -0.75.
| Revenue | 573.28M |
| Gross Profit | 573.28M |
| Operating Income | 0 |
| Net Income | -49.13M |
| EBITDA | -49.55M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
The company has 41.58M in cash and 27.34M in debt, giving a net cash position of 14.24M.
| Cash & Cash Equivalents | 41.58M |
| Total Debt | 27.34M |
| Net Cash | 14.24M |
| Retained Earnings | -355.08M |
| Total Assets | 727.96M |
| Working Capital | 65.21M |
Cash Flow
In the last 12 months, operating cash flow was 38.8M and capital expenditures 0, giving a free cash flow of 38.8M.
| Operating Cash Flow | 38.8M |
| Capital Expenditures | 0 |
| Free Cash Flow | 38.8M |
| FCF Per Share | 0.59 |
Margins
Gross margin is 100%, with operating and profit margins of 0% and -8.57%.
| Gross Margin | 100% |
| Operating Margin | n/a |
| Pretax Margin | -8.57% |
| Profit Margin | -8.57% |
| EBITDA Margin | -8.64% |
| EBIT Margin | n/a |
| FCF Margin | 6.77% |
Dividends & Yields
BVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BVS is $15, which is 63.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 63.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.85 |
| Piotroski F-Score | 5 |